Charles River Laboratories International, Inc. $CRL Shares Sold by Lawson Kroeker Investment Management Inc. NE

Key Points

• Lawson Kroeker Investment Management Inc. NE reduced its holdings in Charles River Laboratories by 9.9%, now owning 50,473 shares, which represents approximately 1.4% of its total portfolio.
• Several institutional investors, including Vanguard and Aberdeen Group, have increased their stakes in Charles River Laboratories, highlighting growing interest from institutional investors.
• Wall Street analysts have upgraded their ratings on Charles River Laboratories, with multiple firms raising their target prices, indicating a generally optimistic outlook for the stock despite recent fluctuations.

Lawson Kroeker Investment Management Inc. NE cut its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 9.9% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 50,473 shares of the medical research company's stock after selling 5,518 shares during the quarter. Charles River Laboratories International makes up approximately 1.4% of Lawson Kroeker Investment Management Inc. NE's holdings, making the stock its 23rd largest holding. Lawson Kroeker Investment Management Inc. NE owned about 0.10% of Charles River Laboratories International worth $7,658,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in CRL. Vanguard Personalized Indexing Management LLC increased its stake in shares of Charles River Laboratories International by 19.7% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 11,678 shares of the medical research company's stock worth $1,772,000 after buying an additional 1,921 shares during the last quarter. Johnson Investment Counsel Inc. increased its position in shares of Charles River Laboratories International by 5.4% in the 2nd quarter. Johnson Investment Counsel Inc. now owns 20,570 shares of the medical research company's stock worth $3,121,000 after purchasing an additional 1,045 shares during the last quarter. Aberdeen Group plc raised its stake in shares of Charles River Laboratories International by 44.8% in the 2nd quarter. Aberdeen Group plc now owns 5,127 shares of the medical research company's stock valued at $778,000 after purchasing an additional 1,586 shares in the last quarter. Blue Trust Inc. lifted its position in shares of Charles River Laboratories International by 6.4% during the second quarter. Blue Trust Inc. now owns 2,562 shares of the medical research company's stock worth $389,000 after purchasing an additional 155 shares during the last quarter. Finally, Callan Family Office LLC acquired a new position in Charles River Laboratories International in the second quarter worth about $340,000. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

CRL has been the topic of several research reports. William Blair upgraded Charles River Laboratories International from a "market perform" rating to an "outperform" rating in a research note on Monday, October 6th. Barclays upgraded Charles River Laboratories International from an "equal weight" rating to an "overweight" rating and raised their price objective for the stock from $165.00 to $195.00 in a research note on Thursday, October 2nd. Jefferies Financial Group upgraded shares of Charles River Laboratories International from a "hold" rating to a "buy" rating and raised their price target for the stock from $142.00 to $195.00 in a research report on Tuesday, September 9th. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Charles River Laboratories International in a research report on Wednesday. Finally, JPMorgan Chase & Co. raised their target price on shares of Charles River Laboratories International from $145.00 to $160.00 and gave the stock a "neutral" rating in a report on Thursday, August 7th. Eight research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $179.93.

Charles River Laboratories International Stock Down 2.9%

CRL stock opened at $167.17 on Friday. The stock has a market cap of $8.23 billion, a PE ratio of -125.69, a price-to-earnings-growth ratio of 4.47 and a beta of 1.50. The firm's 50-day simple moving average is $159.23 and its 200 day simple moving average is $147.55. Charles River Laboratories International, Inc. has a fifty-two week low of $91.86 and a fifty-two week high of $230.02. The company has a quick ratio of 1.10, a current ratio of 1.36 and a debt-to-equity ratio of 0.69.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its earnings results on Wednesday, August 6th. The medical research company reported $3.12 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.50 by $0.62. Charles River Laboratories International had a negative net margin of 1.69% and a positive return on equity of 15.74%. The firm had revenue of $1.03 billion during the quarter, compared to analyst estimates of $983.76 million. During the same period in the previous year, the business posted $2.80 EPS. Charles River Laboratories International's revenue was up .6% on a year-over-year basis. As a group, sell-side analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Insider Buying and Selling

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 800 shares of Charles River Laboratories International stock in a transaction on Monday, August 18th. The stock was sold at an average price of $157.60, for a total transaction of $126,080.00. Following the sale, the executive vice president owned 24,116 shares of the company's stock, valued at $3,800,681.60. The trade was a 3.21% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.30% of the stock is currently owned by corporate insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.